<DOC>
	<DOC>NCT02644629</DOC>
	<brief_summary>The current study wishes to contribute to the applicability of the use of ketamine in a clinical setting by focusing on the efficacy of intra-nasal administration compared with the IV route.</brief_summary>
	<brief_title>Intra-nasal vs. Intra-venous Ketamine Administration</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1. Age 1865 2. Diagnosis of MDD (Major Depressive Disorder), made or affirmed by a senior psychiatrist in Shalvata 3. MADRS score &gt; 20 4. Treated with conventional antidepressant, administered within a formal psychiatric clinic or by a certified psychiatrist. 1. Active or past psychotic disorder, including a history of psychotic affective state 2. Mental Retardation or Autistic Spectrum Disorder 3. Prominent personality disorder 4. Cardiac or neurologic active medical condition, including past CVA/TIA (Cardiovascular Accident/Transient Ischemic Attack) or any other unstable medical condition. 5. Chronic nasal congestion 6. Active or recent drug or alcohol abuse 7. Substantial suicidality in a patient requiring admission but refuses to do so, and signs an "against medical advice" release form as part of clinical evaluation, and does not answer the terms for involuntary admission.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>